Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Upfront Riociguat and Ambrisentan Combination Therapy for Pulmonary Arterial Hypertension: A Safety and Efficacy Pilot Study

NCT03809156 is registered in ClinicalTrials.gov with University of Calgary as lead sponsor.

NCT NCT03809156
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03809156 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Upfront Riociguat and Ambrisentan Combination Therapy for Pulmonary Arterial Hypertension: A Safety and Efficacy Pilot Study
Lead sponsor
University of Calgary
Phase
Phase 4
Overall status
Unknown status
Start date
April 26, 2016
Completion date
January 31, 2021
Enrollment
20 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary hypertension